Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Progenity is going to require many years and tons of capital to get any of its proposed drugs to market. Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the United States and several months later in Europe, and the company plans to launch the product in both markets in the fall. There are no guarantees of that happening, of course. All statements, other than statements of historical facts, included in this press release are forward-looking statements. LONDON, April 28 (Reuters) - Pfizer Inc (PFE.N) has pledged to deliver critical new medicines more quickly in low-income nations, but its first such vaccine effort faces hurdles likely to delay distribution in poorer countries by several years, global health officials told Reuters. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Wednesday before the market open, the company reported better-than-expected third-quarter results. Type a symbol or company name. Given this, the behemoth may not be looking for another oncology company right away. Currently limited by Federal law to investigational use only. Supplemental video of manufacturing vaccines. Progenity is initially targeting ulcerative colitis with this technology. That move will apparently reduce Progenitys operating expenditures by around 70%. By rejecting non-essential cookies, Reddit may still use certain cookies to ensure the proper functionality of our platform. Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA). The PROVENT trial evaluating a median six months of participant follow-up showed a 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%. This informationincluding product informationis intended only for residents of the United States. This webcast may contain forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitor; and our expectations regarding the impact of COVID-19 on our business that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The net loss per share also remained flat at 3 cents per share. Progenity claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. conducted its initial public offering (IPO), 5 Triple A-Rated Stocks to Buy for October, Progenity Stock Is a Zero-or-Hero Holding for Biotech Bidders, Do Not Sell My Personal Information (CA Residents Only). These statements involve known and unknown risks, uncertainties and other factors that could cause Progenitys actual results to differ materially from the forward-looking statements expressed or implied in this press release, including Progenitys ability to successfully develop and commercialize its products under development, the uncertainties inherent in the development process, such as the regulatory approval process, the timing of regulatory filings, and other matters, including the ongoing COVID-19 pandemic, that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations and the availability or commercial potential of Progenitys products, and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC, including but not limited to Progenitys Quarterly Reports on Form 10-Q. 36% of employees would recommend working at Progenity to a friend and 24% have a positive outlook for the business. An Atea buyout also would provide a safety net should Pfizer's own oral combination therapy for COVID, which just entered phase 2/3 trials, fizzle out. To make the world smarter, happier, and richer. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. The CDx test is based on Burning Rock's self-developed next generation sequencing-based liquid biopsy solution, the OncoCompass Target panel. The company had learned during the COVID-19 pandemic that "parallel development" to meet the needs of different regions was possible, Anderson said. The BNT162 program is based on BioNTechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities. If I were Albert Bourla, which would I choose? Lupus nephritis is an autoimmune disorder that's especially harsh on the kidneys, with approximately 10% to 30% of patients experiencing kidney failure within 15 years, despite current therapies. Say Goodbye Not Good Buy to the Progenity Short Squeeze - Insider They include seeking approval for the shot from the WHO, whose authorization is used by governments that don't have a strong domestic drugs regulator, and by nonprofits - such as the global vaccine alliance Gavi - that fund purchases in low-income countries. Chuck Triano Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. Keep . PROG stock closed yesterday at $2.04. This patent covers Progenitys dissociated placental growth factor (PlGF) test, known as Preecludia. In addition, the RSV shot is currently only available in a single-dose vial. At Pfizer, we promise to treat your data with respect and will not share your information with any third party. The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill - Benzinga Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. Forward Looking StatementsThis press release contains forward-looking statements, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Rates of RSV have surged since the pandemic. It had pledged last May to offer its existing portfolio, as well as newly developed drugs and vaccines, at a not-for-profit basis to 45 lower-income countries on a faster timeline than in the past. The autoimmune-focused biotech expects an average annualized net revenue per patient of approximately $65,000. Its first oncology drug, Gavreto, is a once-a-day oral medication for non-small cell lung cancer, as well as certain types of thyroid cancer with a mutation in a specific gene called RET. Pfizer engages in flexible partnership models that includes research collaborations, venture capital investments, academic alliances for drug development, early stage seed funding, establishing incubators, licensing, and spinning out of companies. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Just know that PROG stock is likely to move far and fast, in one direction or the other. For more information, please visit www.BioNTech.de. The post Progenity Stock Is a Zero-or-Hero Holding for Biotech Bidders appeared first on InvestorPlace. Multiple partnerships with MAJOR pharmaceutical companies with Ionis being the only one announced thus far. PROG stock dropped to $9 in July 2020, and closed out the year trading at $5 and change. Reddit and its partners use cookies and similar technologies to provide you with a better experience. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Not for sale in the U.S. Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference. In any event, dont even think about getting on the short side of the trade. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, develop, plan or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. +49 (0)6131 9084 1074[emailprotected]. . A final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. NEW YORK, Oct. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for T, TSLA, PFE, PROG . Progenity intends to use the net proceeds from this offering to support its operations, invest in research and development with respect to its diagnostic technologies and precision medicine platform, and for working capital and general corporate purposes. Progenity, Inc. PROG said in . With pre-tax profit on its COVID-19 vaccine in the high 20% range and Bourla's company guiding for $78 billion to $80 billion in revenue for 2021 (with more than $33 billion of that coming from the vaccine), there's certainly money to be spent on acquisitions. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. But the vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes. Progenity fits just about any definition of a penny stock: it has a low share price, a low market cap, and its as volatile as it gets. EDAP TMS S.A. EDAP reported third-quarter revenues of $11.1 million, almost unchanged from a year-ago period, as lingering COVID-19 impact cut capital equipment sales. Or PROG stock could go to zero. For more than 150 years, we have worked to make a difference for all who rely on us. A Gates Foundation official said that the investment in the RSV program represented a learning process for the organization and the company on the steps needed for more equitable access. Written by And, needless to say, the odds of any early stage drug actually making it through Phase 3 . Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license applications may be filed in any jurisdictions for any potential vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether any such vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such vaccine candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity, including whether the estimated numbers of doses can be manufactured within the projected time periods indicated; whether and when a future production agreement with the United States will be reached; whether and when other supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding any such vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; and competitive developments. Why I Refuse to Chase the Maximum Social Security Benefit, U.S. Money Supply Is Doing Something It Hasn't Done in 90 Years, and It May Signal a Big Move for Stocks, These 2 Banks Are Pulling the Nasdaq Down, Social Security Cuts May Be Coming. AstraZeneca's Tagrisso, which has a similar target, hauled in a whopping $4.3 billion-plus in FY 2020. The U.S. government also can acquire up to an additional 500 million doses. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships. Thinking about buying stock in AT&T, Tesla, Pfizer, Progenity, or Energous Corp? Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11thannual Partnership Opportunities in Drug Delivery(PODD) Conference, October 28-29, 2021 in Boston. Progenitys vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. If the ongoing studies are successful, Pfizer and BioNTech expect to be ready to seek Emergency Use Authorization or some form of regulatory approval as early as October 2020. progenity and pfizer partnership - catalystsolutions.global Let's learn about each other and discover synergies, goals, needs and capabilities. As MacDonald clarified, These tests allow users to see whether any deformities or abnormalities exist with their unborn children. MacDonald also observed that PROG stock had tumbled more than 50% in a single trading session in August. "It's a process. At the same time, aReddit-fueled run-up might be in store for Progenity. Catch it at the right time, and you could quickly double your capital. In addition, the company has entered an agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a '5 Star' firm, and the Legal 500 APAC Guide for Intellectual Property . Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Pfizer Inc. - Pfizer 2023 Annual Meeting of Shareholders Forward-Looking Statements of Pfizer Inc. Pfizer Q1 Earnings Likely Declined 41% - Investopedia This designation was granted based on preliminary data from Phase 1/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies. . A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on July 30, 2021 and was declared effective on August 6, 2021. Pfizer has yet to take a number of steps needed to make the vaccine available in developing countries, according to global health officials and the company. In addition to participating on the panel, the company will also be meeting with potential and existing pharmaceutical partners. Today, more people are surviving cancer than ever before, thanks to advances in diagnosis and treatment. The session will explore oral delivery of biologics and the many technological approaches currently under investigation and showing promising results, including Progenitys Oral Biotherapeutic Delivery System (OBDS), which is designed to enable needle-free systemic delivery of large-molecule biologics in a liquid formulation. Amy Rose It is used to assess patients for preeclampsia (a potentially fatal pregnancy complication). With plenty of financial support and a large seasoned sales force already in place, Pfizer could rapidly capitalize on a buyout of this $5 billion business. Depending on success in clinical trials, todays agreement will enable the delivery of approximately 100 million doses of this vaccine to the American people.. Ever since the first vaccine was developed in 1796 to treat smallpox,1 several different methods have been created to develop successful vaccines. Sylke Maas, Ph.D. Weve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis, said Dr. Albert Bourla, Pfizer Chairman and CEO. With COVID-19 cases rising worldwide, there's a pressing need for an efficacious oral therapy that can be administered not only to hospitalized patients but also to those well enough to be given a prescription as outpatients. Benzinga does not provide investment advice. The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More, Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates, Do Not Sell My Personal Data/Privacy Policy. If you enjoy betting on volatile biotech names, then check out Progenity(NASDAQ:PROG). Investor Relations Preparations for those modifications are just beginning, according to the World Health Organization and the company - which is likely to push back delivery by several years. We are honored to be a part of this effort to provide Americans access to protection from this deadly virus., Expanding Operation Warp Speeds diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year, said HHS Secretary Alex Azar. A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. And we haven't even mentioned Blueprint's other approved drug, which is for a rare disease called mastocytosisand has an addressable market in the U.S. of at least $800 million. Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, Paxlovid, for $5.29 billion, pending and contingent upon regulatory authorization. SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. ("Progenity") (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into privately negotiated . Progenity is currently conducting preclinical studies to demonstrate the bioavailability of its lead candidates PGN-OB1 (adalimumab) and PGN-OB2 (liraglutide, a GLP-1 agonist). The precision-medicine company also has two candidates entering phase 1 studies for non-small cell lung cancer with mutations within a specific gene called EGFR. Pfizer says it is committed to a faster timeline for rolling out medicines to poor nations but acknowledges that there are challenges in meeting such goals. All quotes delayed a minimum of 15 minutes. If You Do This, You Won't Have to Worry About Them, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Pfizer announced a global collaboration with Arvinas, Copyright, Trademark and Patent Information. Forward-looking statements include statements regarding Progenitys expectations regarding the completion and intended use of the proceeds of the registered direct offering. We have built a robust product portfolio through efficient in-house development, clinical laboratory partnerships, and strategic acquisitions. As you can see, Progenity is a small biotechnology company thats in a state of transition. The information contained in this release is as of July 22, 2020. Privacy Policy. Pfizer made a commitment on more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Latest patents confirmed it Icing on the cake..Prog is RANKED the #1 Short Squeeze Candidate According to FINTEL & ORTEX . It has an approved drug with a blockbuster addressable market, and that drug may have optionality for other autoimmune conditions as well (though it's not actively being studied in other diseases at the moment). Start a conversation with us. Pfizer already has multiple compounds aimed at various autoimmune conditions, and this $1.8 billion company seems like an obvious tuck-in acquisition for the pharma giant.